LETM2 and cancer: Figure 4A illustrates the significantly elevated mRNA expression of SLC39A10, SLC22B5, SLC55A2, and SLC30A6 in cancer tissues compared to normal tissues, while the immunohistochemistry data in the right panel further confirm the increased protein levels of these SLCs in cancer tissues.